Pharmacovigilance – A Regulatory Synopsis
When the COVID-19 pandemic was first recognized as a global health crisis in 2020, global Health Authorities (HAs) took innovative steps to deal with it in the best possible manner. Likewise, pharmaceutical companies came up with several vaccines/medicinal products for the benefit of the public. However, registering the products turned out to be quite challenging. To simplify the registration while upkeeping their safety, quality, and efficacy, HAs granted Emergency Use Authorizations (EUAs) to a few vaccines and relevant products.